SGLT-2 Inhibitors: An Emerging Therapeutic Class in the Treatment of Diabetes Part 1 of 2

Summary: In early 2012, the ADA and the EASD issued a joint position statement emphasizing patient specific treatment of hyperglycemia for T2DM. The impetus underlying the new guidelines was the growing appreciation of the complexity surrounding contemporary glycemic management in patients with T2DM. Notwithstanding, the ability of many physicians to adequately select and intensify T2DM treatment regimens has been historically poor, suffering from lack of confidence in managing complex combinations of agents across myriad patient demographics and comorbid conditions. SGLT-2 inhibitors are an emerging class of drug which have been added to this armamentarium. 0.5 CME Credits